AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20945744 — intervention group
Group type: COMPARATOR
Intervention: No bleaching (G I)
Number of subjects: 60
Study 20945744 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination bleaching with sodium ascorbate (G IV)
Number of subjects: 60
Study 20945744 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleaching similar to G II and restored after one week (G III)
Number of subjects: 60
Study 18990044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender Shirodhara (medicated sesame oil with 0.3 volume % of lavender essential oil)
Number of subjects: 16
Study 18990044 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain Shirodhara (plain sesame oil)
Number of subjects: 16
Study 18990044 — intervention group
Group type: COMPARATOR
Intervention: Control supine position
Number of subjects: 16
Study 17086057 — intervention group
Group type: EXPERIMENTAL
Intervention: pegIFNalpha-2a (40KD) plus ribavirin
Number of subjects: 860
Study 17086057 — intervention group
Group type: COMPARATOR
Intervention: pegIFNalpha-2a (40KD) plus placebo
Number of subjects: 860
Study 17086057 — intervention group
Group type: COMPARATOR
Intervention: IFNalpha-2a plus ribavirin
Number of subjects: 860
Study 12657845 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring (Aspect Medical Systems, Natick, MA)
Number of subjects: 99
Study 12657845 — intervention group
Group type: COMPARATOR
Intervention: No BIS monitoring
Number of subjects: 99
Study 10826397 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 31
Study 10826397 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress (exam)
Number of subjects: 31
Study 10826397 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine + Stress
Number of subjects: 31
Study 8638454 — intervention group
Group type: EXPERIMENTAL
Intervention: 75g oral glucose tolerance test (OGTT) performed first
Number of subjects: 0
Study 8638454 — intervention group
Group type: COMPARATOR
Intervention: 50g oral glucose tolerance test (OGTT)
Number of subjects: 0
Study 1993488 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole 3 days a week
Number of subjects: 195
Study 1993488 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg omeprazole once daily
Number of subjects: 195
Study 1993488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study 6149125 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol
Number of subjects: 40
Study 6149125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30901344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral rifampicin and trimethoprim/sulfamethoxazole for 21 days (arm A)
Number of subjects: 61
Study 30901344 — intervention group
Group type: COMPARATOR
Intervention: Observational group (arm B)
Number of subjects: 61
Study 29972753 — intervention group
Group type: EXPERIMENTAL
Intervention: Patisiran (0.3 mg/kg IV every 3 weeks)
Number of subjects: 225
Study 25689953 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited Access Dressing (LAD)
Number of subjects: 55
Study 24268548 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 158
Study 24268548 — intervention group
Group type: EXPERIMENTAL
Intervention: Good patient-physician relationship
Number of subjects: 158
Study 24268548 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a heroin user
Number of subjects: 158
Study 24268548 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of good relationship with physician
Number of subjects: 158
Study 24268548 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine use during treatment
Number of subjects: 158
Study 24268548 — intervention group
Group type: EXPERIMENTAL
Intervention: Hazardous alcohol consumption at enrolment
Number of subjects: 158
Study 22978476 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 316
Study 22978476 — intervention group
Group type: COMPARATOR
Intervention: Sham Electroacupuncture (sham EA)
Number of subjects: 316
Study 22978476 — intervention group
Group type: COMPARATOR
Intervention: No Electroacupuncture (no-EA)
Number of subjects: 316
Study 19806599 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted virtual reality cognitive training program (10 sessions, 2 VR activities using IREX)
Number of subjects: 27
Study 19806599 — intervention group
Group type: COMPARATOR
Intervention: Usual programs in the setting (control group)
Number of subjects: 27
Study 17609909 — intervention group
Group type: EXPERIMENTAL
Intervention: Baoshen Mixture (BSM) given orally thrice a day, 150 mL every time for 15 successive days
Number of subjects: 400
Study 17609909 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control group)
Number of subjects: 400
Study 17609909 — intervention group
Group type: COMPARATOR
Intervention: Both groups received one cycle of chemotherapy program of 28‐30 days with conventional hydratization, alkalization and chloridization
Number of subjects: 400
Study 17378193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild moxibustion combined with cupping therapy
Number of subjects: 0
Study 17378193 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 0
Study 15622367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) 1 g with normal saline before and after angiography
Number of subjects: 94
Study 15622367 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nothing)
Number of subjects: 94
Study 15622367 — intervention group
Group type: COMPARATOR
Intervention: NAC and Placebo in raised SC group
Number of subjects: 94
Study 15622367 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC (i.v. at 1 g)
Number of subjects: 94
Study 15622367 — intervention group
Group type: COMPARATOR
Intervention: Normal SC group (hydration)
Number of subjects: 94
Study 10874267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous RPR 109891
Number of subjects: 233
Study 10874267 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral RPR 109891
Number of subjects: 233
Study 10874267 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous plus oral RPR 109891
Number of subjects: 233
Study 10874267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 9179324 — intervention group
Group type: EXPERIMENTAL
Intervention: Literature-based reading project
Number of subjects: 0
Study 8252506 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide and flutamide
Number of subjects: 603
Study 8252506 — intervention group
Group type: COMPARATOR
Intervention: leuprolide and placebo
Number of subjects: 603
Study 8252506 — intervention group
Group type: EXPERIMENTAL
Intervention: flutamide after progression
Number of subjects: 603
Study 8252506 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide and flutamide at disease progression
Number of subjects: 603
Study 3899677 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinpocetine 40 mg
Number of subjects: 12
Study 3899677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30325677 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided graded Exercise Self-help (GES)
Number of subjects: 19
Study 29172403 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating renalase levels
Number of subjects: 383
Study 29172403 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 383
Study 27859314 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band imaging (study group)
Number of subjects: 100
Study 27859314 — intervention group
Group type: COMPARATOR
Intervention: Standard definition of margins (control group)
Number of subjects: 100
Study 26941545 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐LRP+LIHR
Number of subjects: 60
Study 26941545 — intervention group
Group type: COMPARATOR
Intervention: E‐LRP
Number of subjects: 60
Study 24747090 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased body mass index (BMI)
Number of subjects: 3258
Study 20661162 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic strength training (BST) for 8 weeks, 2 times a week
Number of subjects: 28
Study 20661162 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 19155764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial stenting (Wingspan and Neurolink Stent Systems)
Number of subjects: 0
Study 19155764 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy (including cilostazol)
Number of subjects: 0
Study 17704423 — intervention group
Group type: EXPERIMENTAL
Intervention: LV5FU2 (semimonthly regimen)
Number of subjects: 905
Study 17704423 — intervention group
Group type: COMPARATOR
Intervention: mFU/LV (monthly regimen)
Number of subjects: 905
Study 15185766 — intervention group
Group type: EXPERIMENTAL
Intervention: ACNU
Number of subjects: 0
Study 15185766 — intervention group
Group type: COMPARATOR
Intervention: ACNU plus procarbazine
Number of subjects: 0
Study 11230476 — intervention group
Group type: EXPERIMENTAL
Intervention: Three courses of mitomycin 8 mg/m(2), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) every 21 days.
Number of subjects: 308
Study 11230476 — intervention group
Group type: COMPARATOR
Intervention: Six courses of mitomycin 8 mg/m(2), vinblastine 6 mg/m(2), and cisplatin 50 mg/m(2) every 21 days.
Number of subjects: 308
Study 9746385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg (n = 218)
Number of subjects: 437
Study 9746385 — intervention group
Group type: COMPARATOR
Intervention: E2/NETA (17beta‐oestradiol 2 mg plus norethisterone acetate 1 mg) (n = 219)
Number of subjects: 437
Study 2894492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 500 and 2000 micrograms thrice in 1 day
Number of subjects: 16
Study 2894492 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 750 micrograms thrice daily for 14 days
Number of subjects: 16
Study 2894492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30788847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (60 mg twice daily, reduced from 90 mg twice daily)
Number of subjects: 19220
Study 30788847 — intervention group
Group type: COMPARATOR
Intervention: Placebo (on top of low dose aspirin)
Number of subjects: 19220
Study 30788847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 19220
Study 28575235 — intervention group
Group type: EXPERIMENTAL
Intervention: Active remote monitoring (RM)
Number of subjects: 1650
Study 28575235 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 1650
Study 25639879 — intervention group
Group type: EXPERIMENTAL
Intervention: Submicron indomethacin 40 mg
Number of subjects: 40
Study 25639879 — intervention group
Group type: EXPERIMENTAL
Intervention: Submicron indomethacin 20 mg
Number of subjects: 40
Study 25639879 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 50 mg
Number of subjects: 40
Study 23815915 — intervention group
Group type: EXPERIMENTAL
Intervention: VD regimen (bortezomib combined with dexamethasone)
Number of subjects: 59
Study 23815915 — intervention group
Group type: COMPARATOR
Intervention: VAD regimen (vincristine, doxorubicin, and dexamethasone)
Number of subjects: 59
Study 22384544 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) at a daily dose of 1.2 g, twice daily (large dose group)
Number of subjects: 80
Study 22384544 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) at a daily dose of 0.6 g, twice daily (normal dose group)
Number of subjects: 80
Study 22384544 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) (both doses)
Number of subjects: 80
Study 22384544 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine therapy only)
Number of subjects: 80
Study 19524823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded Herbst followed by fixed appliances (BH + FA)
Number of subjects: 56
Study 19524823 — intervention group
Group type: EXPERIMENTAL
Intervention: Headgear followed by fixed appliances and Class II elastics (HG + FA)
Number of subjects: 56
Study 19524823 — intervention group
Group type: COMPARATOR
Intervention: Natural growth changes in Class II controls
Number of subjects: 56
Study 16721690 — intervention group
Group type: EXPERIMENTAL
Intervention: Serrated adenomas (SA) with size <10 mm
Number of subjects: 71
Study 16721690 — intervention group
Group type: COMPARATOR
Intervention: Serrated adenomas (SA) with size >=10 mm
Number of subjects: 71
Study 16721690 — intervention group
Group type: EXPERIMENTAL
Intervention: Protruded serrated adenomas
Number of subjects: 71
Study 16721690 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial serrated adenomas
Number of subjects: 71
Study 16721690 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological features of serrated adenomas
Number of subjects: 71
Study 16721690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysplasia levels in serrated adenomas
Number of subjects: 71
Study 16721690 — intervention group
Group type: EXPERIMENTAL
Intervention: IV and III L pit SAs
Number of subjects: 71
Study 16721690 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperplastic polyps-like SAs
Number of subjects: 71
Study 16721690 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypia in II pit SAs
Number of subjects: 71
Study 15650469 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 42
Study 15650469 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical heat acupuncture (EH)
Number of subjects: 42
Study 15650469 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 12645048 — intervention group
Group type: EXPERIMENTAL
Intervention: Criminal anchoring in suspect statements
Number of subjects: 0
Study 12645048 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-temporal sequence of events in statements
Number of subjects: 0
Study 10601068 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin plus isosorbide 5-mononitrate (250 microg/hour + 40 mg/12 hours)
Number of subjects: 60
Study 10601068 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin alone (placebo)
Number of subjects: 60
Study 10601068 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin plus isosorbide 5-mononitrate
Number of subjects: 60
Study 9362350 — intervention group
Group type: EXPERIMENTAL
Intervention: TIPSS
Number of subjects: 58
Study 9362350 — intervention group
Group type: COMPARATOR
Intervention: VBL
Number of subjects: 58
Study 1313860 — intervention group
Group type: EXPERIMENTAL
Intervention: eight‐drugs‐in‐one‐day
Number of subjects: 35
Study 1313860 — intervention group
Group type: COMPARATOR
Intervention: PCV
Number of subjects: 35
Study 2427983 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiochemotherapy (4 courses + 40 Gy EF)
Number of subjects: 235
Study 2427983 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (4 courses + 20 Gy EF)
Number of subjects: 235
Study 2427983 — intervention group
Group type: EXPERIMENTAL
Intervention: TNI 40 Gy
Number of subjects: 235
Study 2427983 — intervention group
Group type: COMPARATOR
Intervention: 6 courses chemotherapy + 20 Gy IF
Number of subjects: 235
Study 2427983 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation therapy 20 Gy IF
Number of subjects: 235
Study 2427983 — intervention group
Group type: COMPARATOR
Intervention: 2 courses chemotherapy
Number of subjects: 235
Study 30055903 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine infusion (mean final dose 4·68 mg/h)
Number of subjects: 106
Study 30055903 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline infusion
Number of subjects: 106
Study 27665230 — intervention group
Group type: COMPARATOR
Intervention: IONIS‐APO(a)Rx
Number of subjects: 122
Study 27665230 — intervention group
Group type: COMPARATOR
Intervention: IONIS‐APO(a)‐LRx 10 mg
Number of subjects: 122
Study 27665230 — intervention group
Group type: COMPARATOR
Intervention: IONIS‐APO(a)‐LRx 20 mg
Number of subjects: 122
Study 27665230 — intervention group
Group type: COMPARATOR
Intervention: IONIS‐APO(a)‐LRx 40 mg
Number of subjects: 122
Study 25047762 — intervention group
Group type: EXPERIMENTAL
Intervention: A combination of nuclear β-catenin and atypical scores
Number of subjects: 136
Study 25047762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear β-catenin
Number of subjects: 136
Study 25047762 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical scores
Number of subjects: 136
Study 25047762 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear β-catenin immunoreactivity
Number of subjects: 136
Study 22440085 — intervention group
Group type: EXPERIMENTAL
Intervention: Atonia Index (quantitative analysis of chin EMG during REM sleep)
Number of subjects: 27
Study 22440085 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (no specific intervention mentioned)
Number of subjects: 27
Study 19550338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-inspired oxygen concentration
Number of subjects: 142
Study 19550338 — intervention group
Group type: COMPARATOR
Intervention: High-inspired oxygen concentration
Number of subjects: 142
Study 18757085 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg/day
Number of subjects: 5926
Study 18757085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5926
Study 15750445 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 63
Study 15750445 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 63
Study 12872466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy during colonoscopy (Group B)
Number of subjects: 264
Study 12872466 — intervention group
Group type: COMPARATOR
Intervention: No fluoroscopy during colonoscopy (Group A)
Number of subjects: 264
Study 10558453 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretics and beta-blockers
Number of subjects: 0
Study 10558453 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 10558453 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 0
Study 10558453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (in combination with other antihypertensive drugs)
Number of subjects: 0
Study 10558453 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and Atenolol
Number of subjects: 0
Study 10558453 — intervention group
Group type: COMPARATOR
Intervention: Dihydropyridine
Number of subjects: 0
Study 7867364 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based recommendations from clinical trials
Number of subjects: 0
Study 1958599 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 30
Study 1958599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7181807 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system‐scopolamine (1.0 mg over 3 days)
Number of subjects: 6
Study 7181807 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal therapeutic system‐scopolamine (second treatment regimen)
Number of subjects: 6
Study 7181807 — intervention group
Group type: COMPARATOR
Intervention: Placebo (four treatments)
Number of subjects: 6
Study 31428820 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P6
Number of subjects: 549
Study 31428820 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 549
Study 27193248 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit video-based warm-up
Number of subjects: 30
Study 27193248 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit video-based warm-up
Number of subjects: 30
Study 27193248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video-based warm-up)
Number of subjects: 30
Study 25337966 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal (AC) technique with 8 mL of 2% lidocaine with epinephrine 1:400,000
Number of subjects: 102
Study 25337966 — intervention group
Group type: COMPARATOR
Intervention: Peri-saphenous branch of the descending genicular artery (Peri-SBDGA) technique with 8 mL of 2% lidocaine with epinephrine 1:400,000
Number of subjects: 102
Study 23810152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized raw whole egg powder (1 teaspoon daily from 4 to 8 months)
Number of subjects: 86
Study 23810152 — intervention group
Group type: COMPARATOR
Intervention: Rice powder (1 teaspoon daily from 4 to 8 months)
Number of subjects: 86
Study 23810152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasteurized raw whole egg powder
Number of subjects: 86
Study 21675058 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Sedative Interruption (DSI)
Number of subjects: 22
Study 21675058 — intervention group
Group type: COMPARATOR
Intervention: Continuous Sedation (CS)
Number of subjects: 22
Study 19755166 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 49
Study 19755166 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 49
Study 19755166 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 49
Study 16723518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuit eye movement during visual flow stimuli
Number of subjects: 0
Study 16723518 — intervention group
Group type: COMPARATOR
Intervention: Retinal flow stimuli
Number of subjects: 0
Study 16723518 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursuit eye movement
Number of subjects: 0
Study 16723518 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotational flow relative to the head
Number of subjects: 0
Study 15028375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 100
Study 15028375 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 100
Study 11585144 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐META/MMA‐TBB resin cement, bonded through the root canal (group A)
Number of subjects: 22
Study 11585144 — intervention group
Group type: EXPERIMENTAL
Intervention: 4‐META/MMA‐TBB resin cement, bonded extra-orally and replanted (group B)
Number of subjects: 22
Study 9509698 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary angioplasty
Number of subjects: 0
Study 9509698 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolytic therapy
Number of subjects: 0
Study 8015504 — intervention group
Group type: EXPERIMENTAL
Intervention: dl-norgestrel alone (0.075 mg/day) continuously for two cycles
Number of subjects: 26
Study 8015504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (dl-norgestrel and estradiol-17 beta) for six cycles
Number of subjects: 26